Get the Stockscreener App
16.37
4.99%
-0.86
Mesoblast Ltd Adr stock is traded at $16.37, with a volume of 185.35K.
It is down -4.99% in the last 24 hours and down -9.26% over the past month.
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.
See More
Previous Close:
$17.23
Open:
$17.15
24h Volume:
185.35K
Relative Volume:
0.42
Market Cap:
$2.09B
Revenue:
$7.50M
Net Income/Loss:
$-81.89M
P/E Ratio:
0.3088
EPS:
53.0176
Net Cash Flow:
$-63.58M
1W Performance:
-8.55%
1M Performance:
-9.26%
6M Performance:
+151.46%
1Y Performance:
+706.40%
1-Day Range:
$16.30
$17.23
1-Week Range:
$16.30
$18.49
52-Week Range:
$1.9098
$22.00
Mesoblast Ltd Adr Stock (MESO) Company Profile
Compare MESO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MESO
Mesoblast Ltd Adr
|
16.37 | 2.09B | 7.50M | -81.89M | -63.58M | 53.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Mesoblast Ltd Adr Stock (MESO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-23-24 | Downgrade | Jefferies | Buy → Hold |
| Sep-24-24 | Upgrade | Maxim Group | Hold → Buy |
| Aug-29-24 | Upgrade | Jefferies | Hold → Buy |
| Jul-23-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-31-23 | Upgrade | Jefferies | Hold → Buy |
| Aug-07-23 | Downgrade | Maxim Group | Buy → Hold |
| Aug-04-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-04-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Mar-09-23 | Initiated | William Blair | Outperform |
| Dec-06-22 | Downgrade | Jefferies | Buy → Hold |
| Sep-06-22 | Initiated | Piper Sandler | Overweight |
| Apr-07-21 | Upgrade | Maxim Group | Hold → Buy |
| Dec-22-20 | Downgrade | Maxim Group | Buy → Hold |
| Dec-04-20 | Downgrade | Chardan Capital Markets | Neutral → Sell |
| Oct-22-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Aug-14-20 | Reiterated | Maxim Group | Buy |
| May-28-20 | Reiterated | H.C. Wainwright | Buy |
| Jan-31-19 | Resumed | H.C. Wainwright | Buy |
| Mar-22-18 | Downgrade | Credit Suisse | Neutral → Underperform |
| Feb-28-18 | Reiterated | Cantor Fitzgerald | Buy |
| Aug-31-17 | Initiated | Oppenheimer | Outperform |
| Jun-08-17 | Initiated | Cantor Fitzgerald | Buy |
View All
Mesoblast Ltd Adr Stock (MESO) Latest News
Ryoncil® FDA Approval and Market Launch Highlighted at Tandem Transplantation Meetings - GlobeNewswire Inc.
Why Mesoblast Ltd ADR (NASDAQ: MESO) Is Worth Including On Your Watchlist - Marketing Sentinel
The 98.76% Simple Moving Average of Mesoblast Ltd ADR’s (MESO) Stock in the Past 200 Days - The News Heater
21 Best-Performing Small-Cap Stocks for February 2025 - NerdWallet
Mesoblast Ltd ADR (NASDAQ:MESO) Shares Are Up 10.24 Percent In A Week – But Can The Gains Continue? - Marketing Sentinel
Why are Mesoblast shares in a trading halt? - The Motley Fool Australia
Mesoblast Limited Initiates Trading Halt Pending Financing Announcement - TipRanks
ASX December health sector winners… and a 91pc drop for a trial-flopped stock - Stockhead
MESO Stock Surges 80% In A Month After FDA Approval Of GVHD Drug - Barchart
Mesoblast (NASDAQ:MESO) Shares Gap UpWhat's Next? - MarketBeat
ASX healthcare 2024 winners and losers, plus what’s next for 2025 - Stockhead
Investors: What’s The Real Deal With W & T Offshore Inc (NYSE: WTI) - Stocks Register
What Analysts Think About TC BioPharm (Holdings) plc ADR (NASDAQ: TCBP)’s Potential Raise - Stocks Register
No Stopping Argo Blockchain Plc ADR (NASDAQ: ARBK)’s Stock Plunged? - Stocks Register
NIO Inc ADR (NYSE: NIO) Stock Forecast: Could Pass $8 In A Year - Stocks Register
If You Don’t Buy Safe Pro Group Inc (NASDAQ: SPAI) Now, You’ll Regret It Later - Stocks Register
What Do Analysts Think About Aspen Aerogels Inc’s (NYSE:ASPN) Future? - Stocks Register
Would I Buy Opendoor Technologies Inc (NASDAQ: OPEN) Stock At Any Time In The Future? - Stocks Register
Tempest Therapeutics Inc (NASDAQ: TPST) Investors Should Be Worried About This. - Stocks Register
Cytek Biosciences, Emergent BioSolutions, Radiopharm Theranostics And Other Big Stocks Moving Higher On Monday - Benzinga
Petco Health and Wellness Co Inc (NASDAQ: WOOF): A Hidden Gem Despite Volatility - Stocks Register
Where Do Analysts See Gamestop Corporation (NYSE: GME) Heading? - Stocks Register
Mesoblast Stock Soars to 52-Week High, Hits $19.15 - Investing.com
Here’s Why Lineage Cell Therapeutics Inc (AMEX: LCTX) Is An Attractive Investment Right Now - Stocks Register
No Stopping Editas Medicine Inc (NASDAQ: EDIT)’s Stock Plunged? - Stocks Register
What Do Analysts Think About Therealreal Inc’s (NASDAQ:REAL) Future? - Stocks Register
What Awaits These 4 Biotech Stocks That More Than Doubled In 2024 - Barchart
Why the Mesoblast share price is diving 18% after an FDA win - The Motley Fool Australia
Mesoblast share price rockets 30% on big US FDA news - The Motley Fool Australia
Mesoblast stock soars to 52-week high, hits $12.21 - Investing.com
Mesoblast Stock Soars to 52-Week High, Hits $12.19 - Investing.com
Best Momentum Stocks to Buy for November 26th - Yahoo Finance
Investors Heavily Search Sea Limited Sponsored ADR (SE): Here is What You Need to Know - Yahoo Finance
Mesoblast stock soars to 52-week high, hits $11.1 - Investing.com
Mesoblast files annual report and meeting notice - Investing.com India
JPMorgan Takes Substantial Stake in Mesoblast Ltd - TipRanks
Mesoblast stock soars to 52-week high, hits $8.7 - Investing.com
Mesoblast to raise $50m from top shareholder for product launch - Capital Brief
What Makes Holcim Ltd Unsponsored ADR (HCMLY) a Strong Momentum Stock: Buy Now? - Yahoo Finance
Mesoblast stock gains momentum ahead of 2025 PDUFA dateJefferies - Investing.com
Australia stocks higher at close of trade; S&P/ASX 200 up 0.50% - Investing.com
Mesoblast: Rolling The Dice On Cellular Medicines (NASDAQ:MESO) - Seeking Alpha
Check Up: Big breakthrough in acne treatment, and recent ASX biotech winners - Stockhead
Mesoblast Limited: Back From The Dead (NASDAQ:MESO) - Seeking Alpha
Australia stocks higher at close of trade; S&P/ASX 200 up 0.99% - Investing.com
Why Westport Fuel Systems Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session - Benzinga
11 Best ASX Stocks To Buy Now - Yahoo Finance
Sea Limited (SE) to Report Q4 Earnings: What's in Store? - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
10 Best Australian Stocks To Buy - Yahoo Finance
Mesoblast Ltd receives Investment Bank Analyst Rating Update By Investing.com - Investing.com
Mesoblast Ltd Adr Stock (MESO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):